Ocata Therapeutics Inc fka OCAT

[chuckanutman]

This post keeps coming up on OCAT internet-search.

"OCATA Therapeutics PPS projections based on TOTAL ADDRESSABLE MARKET(TAM) for Pivotal SMD and Phase 2 AMD and upcoming milestones 2015/2016

2nd quarter 2015: $35.00 plus
Based on upcoming OCAT Milestones in Q2:
1. SMD granted SPA by USFDA.
2. First SMD patient treated in Pivotal Trial.
3. First AMD patient treated in phase 2 Trial.
4. Asian patients Data published.
5. Phase 1 complete data set released of all 38 patient AMD trial.
6. JV Non core assets.
7. Data published for Tuft's dog trials based on OCAT cell therapies for Lupus, Chron's etc.
8. IND filed with FDA for RPC's to cure blindness even in patients with dead rods and cones.
9. Multiple additional sites for both here and EU for both SMD and AMD trials.

3rd quarter 2015: $70.00 plus
1. EU Pivotal Trial SMD Therapy partnership with major EU Big PHARMA.
2. US partnership for AMD therapy.
3. MS mice data published in peer review Journal.

4th quarter 2015: $ 100.00+
1. EU halts orphan SMD pivotal trial and grants OCAT marketing authorization for all of EU based on overwhelming safety and efficacy.
2. US FDA halts orphan SPA SMD therapy and grants approval based on overwhelming safety and efficacy.
3. FDA grants breakthrough designation for OCAT AMD therapy.
4. Dr. Lanza and Dr. Langer receive Nobel.

2016 to be continued...

Sentiment: Strong Buy"